Evidence map›Paper›PMID 32517255›Full record

ArticlePharmaceutics2020

Hot Melt Coating of Amorphous Carvedilol.

Jacob Bannow, Lina Koren, Sharareh Salar-Behzadi, Korbinian Löbmann, Andreas Zimmer, Thomas Rades

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Amorphous Drug-Polymer Salts.Pharmaceutics · 2021
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Jacob BannowDepartment of Pharmacy, University of Copenhagen, Universitetsparken 2, DK-2100 Copenhagen, Denmark.ORCID 0000-0002-7371-5803
Lina KorenInstitute of Pharmaceutical Sciences/Pharmaceutical Technology and Biopharmacy, Karl-Franzens-University of Graz, Universitätsplatz 1, A-8010 Graz, Austria.
Sharareh Salar-BehzadiInstitute of Pharmaceutical Sciences/Pharmaceutical Technology and Biopharmacy, Karl-Franzens-University of Graz, Universitätsplatz 1, A-8010 Graz, Austria.
Korbinian LöbmannDepartment of Pharmacy, University of Copenhagen, Universitetsparken 2, DK-2100 Copenhagen, Denmark.ORCID 0000-0002-8710-6347
Andreas ZimmerInstitute of Pharmaceutical Sciences/Pharmaceutical Technology and Biopharmacy, Karl-Franzens-University of Graz, Universitätsplatz 1, A-8010 Graz, Austria.ORCID 0000-0003-3127-287X
Thomas RadesDepartment of Pharmacy, University of Copenhagen, Universitetsparken 2, DK-2100 Copenhagen, Denmark.ORCID 0000-0002-7521-6020
University of Copenhagen · DKUniversity of Graz · AT

Funding

Lundbeckfonden R218-2016-1252
6 · The paper itself

Abstract

The use of amorphous drug delivery systems is an attractive approach to improve the bioavailability of low molecular weight drug candidates that suffer from poor aqueous solubility. However, the pharmaceutical performance of many neat amorphous drugs is compromised by their tendency for recrystallization during storage and lumping upon dissolution, which may be improved by the application of coatings on amorphous surfaces. In this study, hot melt coating (HMC) as a solvent-free coating method was utilized to coat amorphous carvedilol (CRV) particles with tripalmitin containing 10% (

Indexed as

amorphous drug deliveryamorphous solidsamorphous stabilitycarvediloldynamic in vitro lipolysishot melt coating (HMC)solid-statetripalmitin

Identifiers

PMID32517255
PMCPMC7356097
OpenAlexW3033807795

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.